risk factors for hepatitis, 156, 157-158, 159

screening and counseling

recommendations of, 82-83, 84, 156-157, 159, 183

state cooperative agreements with, 4, 7, 42, 54, 57, 64-66, 67

surveillance initiatives, 4, 6, 7-8, 42-43, 44, 45, 50, 57, 58, 59-61, 63, 64, 65-66, 67, 68, 69, 70-71

vaccination recommendations and programs, 12, 110-111, 124-125, 126, 128-129, 134, 136, 153, 157

VFC program, 128-129, 130, 131, 134

Centers for Medicare and Medicaid Services, 129, 149.

See also Medicaid;

Medicare

Central nervous system demyelinating disorders, 32

Chicago, 28, 116, 121

Childhood Immunization Initiative, 126

Children

asymptomatic infections, 47

HBV, 23, 25, 30, 47, 116-117, 128-132

HCV, 51

information systems on, 127-128

progression of infection in, 46, 117, 118

vaccination, 4, 9, 10, 25, 30, 93, 97, 110, 111, 112, 116-117, 128-132, 134

Children’s Health Insurance Program (CHIP), 128, 129-132, 172

Chinese Americans, 68, 81, 82, 86, 89, 90, 92, 174

Chronic infections.

See also Hepatitis B;

Hepatitis C;

Knowledge and awareness of chronic hepatitis

age at exposure and potential for, 19, 22, 46, 51, 82-83, 113, 117, 118, 156

asymptomatic nature of, 3, 23, 24, 25, 27, 28, 47, 50, 51, 52, 53, 55, 90, 159, 162

clinical outcomes, 23;

see also Liver cancer and liver cirrhosis

prevalence and incidence, 1, 34, 121

surveillance, 25, 44, 51-54, 59, 64, 67, 71

Clinical outcomes.

See also Liver cancer and liver cirrhosis

age at exposure and, 19, 22, 46, 51, 82-83, 113, 117, 118, 156

knowledge of, 80, 83, 89

Coinfection

HBV and HCV, 23, 29, 30, 32

HIV and hepatitis, 23, 29, 72, 81-82, 190

Collaborative Injection Drug User Study Drug User Intervention Trial, 94, 95

Colorado, 58

Committee task

approach, 32-35

charge to committee, 30-32

Community

health centers, 16, 149, 186-189

outreach, 9, 90, 91-92, 97, 98-99, 101

screening and testing programs, 5, 13

Confidentiality safeguards, 43-44, 65

Connecticut, 55, 58, 122

Contacts.

See also Partner services

education of, 97, 98

vaccination, 54, 57-58, 62, 93, 117, 119-120

Correctional facilities.

See also Incarcerated populations

educational programs on viral hepatitis, 88-89, 99-100

recommendations, 16

viral hepatitis services, 6, 13, 14, 16, 149, 184-186

Counseling, 5, 14, 31, 62, 63, 84, 85, 87, 95, 124, 134, 148, 151, 152, 157, 160, 163, 168, 171, 172, 177, 179, 180, 181, 186, 189, 191

D

Deaths, preventable, by disease, 20

Denmark, 121

Department of Health and Human Services, 110

National Vaccine Program Office, 126

Office of Minority Health and Health Disparities, 2, 30, 149, 152

Department of Justice, 6, 16, 149, 186

Department of Veterans Affairs (VA), 2, 28, 30, 94, 130, 171, 172

Detroit, 121

Discrimination. See Stigmatization and discrimination

Drug treatment programs and facilities.

See also Illicit-drug users

educational programs on viral hepatitis, 8, 88-89, 95-96, 100, 176



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement